|Bid||8.00 x N/A|
|Ask||13.00 x N/A|
|Day's Range||8.02 - 9.90|
|52 Week Range||8.00 - 100.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||180.00|
Aptamer Group ( LON:APTA ) First Half 2023 Results Key Financial Results Revenue: UK£1.02m (down 26% from 1H 2022). Net...
Aptamer Group PLC (AIM:APTA) CEO Dr Arron Tolley speaks to Proactive's Thomas Warner following the release of the company's interim results.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
10 January 2023 Aptamer Group plc(“Aptamer”, the “Company” or the “Group”) Appointment of Interim Chief Commercial Officer Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the appointment of Derek Smith as Interim Chief Commercial Officer, effective as of 1st January 2023. Derek joined the Company in 2018 as Director of Global Sales and has since become a vital part of the Aptamer team, overseeing the devel
UK firm links with up global drug firms to make synthetic antibodies capable of binding to targets such as tumour cells